MFSD1

MFSD1 is a lysosomal major facilitator superfamily transporter that functions as a dipeptide uniporter, exporting cationic, neutral, and anionic dipeptides—products of lysosomal proteolysis—back to the cytoplasm for biosynthetic reuse (PMID:38839979, PMID:38507452). MFSD1 forms an obligate heterodimeric complex with the accessory subunit GLMP, which stabilizes MFSD1 in lysosomes and is required for its normal expression; it additionally associates with GIMAP5, and loss of any member of this complex causes lymphopenia, liver disease, and extramedullary hematopoiesis in mice (PMID:31661432, PMID:38055739). Lysosomal targeting of MFSD1 depends on a dileucine-based sorting motif, and its cryo-EM structure in the outward-open, dipeptide-bound state reveals the structural determinants of dipeptide selectivity and the GLMP interaction interface (PMID:31661432, PMID:38839979). MFSD1 also promotes recycling of inactive β1 integrin to the cell surface, and its loss increases integrin activation, focal adhesion turnover, and metastatic potential in mouse tumor models (PMID:35211397).

1. 2016 Low

   Before any functional data, computational analysis classified MFSD1 as a putative 12-transmembrane solute carrier of the major facilitator superfamily, with neuronal expression responsive to amino acid deprivation, establishing it as a candidate nutrient transporter.

   Evidence Phylogenetic analysis, homology modelling, immunofluorescence, and amino acid deprivation in mouse primary cortical cells

   PMID:27981419

   Open questions at the time

   • Predictions based on homology modelling without direct structural data
   • No transport substrate identified
   • Neuronal plasma membrane localization was later superseded by lysosomal localization findings
2. 2019 High

   The first loss-of-function study established that MFSD1 is a lysosomal membrane protein requiring a dileucine sorting motif for targeting, that it forms a stabilizing complex with GLMP, and that its loss causes splenomegaly and severe liver disease in mice—demonstrating physiological importance but leaving the transport substrate unknown.

   Evidence Mfsd1 knockout mice, lysosomal proteomics, co-immunoprecipitation, mutagenesis of sorting motif, immunofluorescence

   PMID:31661432

   Open questions at the time

   • No transport substrate identified
   • Mechanism linking MFSD1 loss to liver disease unresolved
   • Whether GLMP is a passive stabilizer or active functional partner not determined
3. 2022 Medium

   A cell-biological study revealed that MFSD1 promotes recycling of inactive β1 integrin to the cell surface, connecting its loss to enhanced tumor cell migration and metastasis—an unexpected role beyond solute transport.

   Evidence MFSD1 knockout mouse metastasis models, integrin recycling assays, focal adhesion turnover measurements

   PMID:35211397

   Open questions at the time

   • Whether the integrin recycling phenotype is a direct effect of MFSD1 or secondary to lysosomal dysfunction is unclear
   • Single-lab finding not yet independently replicated
   • Molecular mechanism by which a transporter regulates integrin trafficking not defined
4. 2023 High

   Proteomic and genetic studies expanded the MFSD1–GLMP complex to include GIMAP5, showing that all three proteins are interdependent for expression and that loss of any one recapitulates lymphopenia, liver pathology, and lipid deposition—establishing a tripartite lysosomal complex essential for immune and metabolic homeostasis.

   Evidence ENU mutagenesis screen, germline knockout mouse models for Mfsd1/Glmp/Gimap5, mass spectrometry

   PMID:38055739

   Open questions at the time

   • Whether GIMAP5 modulates MFSD1 transport activity or acts independently downstream is unknown
   • The mechanism linking lysosomal dipeptide export to lymphocyte development is not defined
5. 2024 High

   Two independent studies converged to identify MFSD1 as a lysosomal dipeptide uniporter: untargeted and targeted metabolomics showed dipeptide accumulation in MFSD1-deficient lysosomes, electrophysiology and proteoliposome reconstitution demonstrated direct uniport of cationic, neutral, and anionic dipeptides, and cryo-EM of the MFSD1–GLMP heterodimer in the outward-open state revealed the structural basis for dipeptide binding and selectivity.

   Evidence Cryo-EM structure, proteoliposome reconstitution, Xenopus oocyte electrophysiology, whole-cell patch-clamp in HEK293 cells, untargeted and targeted metabolomics, molecular dynamics simulations

   PMID:38507452 PMID:38839979

   Open questions at the time

   • Inward-open and occluded conformational states have not been resolved structurally
   • Physiological regulation of MFSD1 transport activity (e.g., by luminal pH, post-translational modifications) is undefined
   • Relative contributions of MFSD1 versus other peptide transporters (e.g., PQLC2, PHT1) to lysosomal peptide efflux are not quantified

• Key unresolved questions include the full conformational cycle of MFSD1 during transport, whether GIMAP5 directly modulates transport function, the molecular basis connecting dipeptide export to integrin recycling and immune phenotypes, and whether MFSD1 mutations cause human disease.
• No human Mendelian disease linked to MFSD1 mutations
• Structural basis for the complete transport cycle remains incomplete
• Causal pathway from dipeptide accumulation to lymphopenia and liver disease not delineated